Onderneming Xintela AB (publ) Nasdaq Stockholm
Aandelen
SE0007756903
Biotechnologie & Medisch Onderzoek
Vakgebied
Verkoop per activiteit
SEK in miljoen | 2022 | Gewicht | 2023 | Gewicht | Delta |
---|---|---|---|---|---|
Stem Cell Therapies
100,0
%
| 0 | nan % | 0 | 100,0 % | - |
Verkoop per regio
SEK in miljoen | 2022 | Gewicht | 2023 | Gewicht | Delta |
---|---|---|---|---|---|
Sweden
100,0
%
| 0 | nan % | 0 | 100,0 % | - |
Managers
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Founder | 67 | 01-01-09 | |
Gunnar Telhammar
DFI | Director of Finance/CFO | 63 | 01-01-13 |
Thomas Areschoug
PRN | Corporate Officer/Principal | 52 | 01-03-17 |
Besturend
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Lars Olof Hedbys
BRD | Director/Board Member | 67 | 01-01-21 |
Chairman | 67 | 01-01-11 | |
Director/Board Member | 64 | 01-01-22 | |
Director/Board Member | 61 | 01-01-21 | |
Director/Board Member | 62 | 01-01-22 |
Aandelenklasse
Stemming | Aantal | Vrij verhandelbaar | Bedrijfseigen aandelen | Drijvend Totaal | |
---|---|---|---|---|---|
Aandeel A | 1 | 567 006 473 | 177 368 068 ( 31,28 %) | 0 | 31,28 % |
Bedrijfsgegevens
Bedrijven van de groep
Naam | Categorie en sector |
---|---|
Targinta AB
Targinta AB BiotechnologyHealth Technology Part of Xintela AB, Targinta AB develops targeting and toxin-armed antibodies for cancer. The private company is based in Lund, Sweden. Peter Ekolind has been the CEO of the Swedish company since 2022. |
Biotechnology
|
Sector
Vaira. 1 jan. | Kapi. | |
---|---|---|
+23,37% | 46,71 mld. | |
+48,83% | 41,8 mld. | |
-0,94% | 41,52 mld. | |
-5,86% | 29,55 mld. | |
+11,29% | 25,78 mld. | |
-20,92% | 19,26 mld. | |
+3,20% | 12,14 mld. | |
-2,67% | 12,08 mld. | |
+30,23% | 11,98 mld. |